This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46–58.
D’Souza A, Dispenzieri A, Wirk B, Zhang M, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33:3741.
Kastritis E, Minnema MC, Dimopoulos M, Merlini G, Theodorakakou F, Fotiou D, et al. Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study by the European Myeloma Network. Blood. 2021;138:2730.
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136:71–80.
Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Osman K, Pan S, et al. Bendamustine with dexamethasone in relapsed/refractory systemic light-chain amyloidosis: results of a phase II study. J Clin Oncol 2020;38:1455.
Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130:597–605.
Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone Win the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128:1059–62.
Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D’souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023;13:172.
Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, et al. Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. Blood J. 2024;143:734–7.
Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024;109:906–14.
Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, et al. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study. Am J Hematol. 2022;97:1189–99.
Staron A, Burks EJ, Szalat RE, Sanchorawala V. Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab. Blood. 2023;142:3405.
Author information
Authors and Affiliations
Contributions
GSM, MYM, and RC conceived the study design. GSM collected patient data from electronic medical records. DB, MYM, MSM, JR, SL, and RC performed patient care. GSM wrote the first draft of the manuscript. DB, MYM, MSM, JR, SL, and RC critically reviewed the first draft and approved the final draft of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mellgard, G.S., Bhutani, D., Mapara, M.Y. et al. High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02301-7
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-024-02301-7